P3 Health Partners appoints CEO Aric Coffman to board following director resignation

P3 Health Partners Inc. (NASDAQ:PIII) announced the appointment of Dr. Aric Coffman, the company’s Chief Executive Officer, to its board of directors. The decision was made Tuesday after Dr. Sherif Abdou resigned from the board, effective the same day, according to a statement released through a Securities and Exchange Commission filing. According to InvestingPro analysis, the company currently trades near its 52-week low of $6.00 and appears undervalued based on its Fair Value assessment.

Dr. Abdou’s transition services agreement with the company ended on April 30, 2025, and his services have since concluded. The board’s Nominating Committee unanimously recommended Dr. Coffman to fill the vacancy created by Dr. Abdou’s departure.

The board approved Dr. Coffman’s appointment on Monday. He will serve as a Class I director with a term set to expire in 2028. The company stated there are no arrangements or understandings between Dr. Coffman and any other party related to his selection as a director.

Dr. Coffman does not qualify as an independent director under applicable exchange listing standards due to his role as Chief Executive Officer. As a result, he is not expected to serve on any board committees. The company also noted that Dr. Coffman will not receive additional compensation for his service on the board.

This information is based on a press release statement included in the company’s SEC filing.

In other recent news, P3 Health Partners Inc. reported its Q1 2025 earnings, revealing a total revenue of $373 million, which missed the forecast of $358.76 million. Despite a 4% year-over-year revenue decline, the company achieved significant operational improvements, including an 18% reduction in operating expenses. The company ended the first quarter with approximately $40 million in cash, but analysts from TD Cowen project that P3 Health will require additional capital in 2025 and 2026. Following the earnings results, TD Cowen adjusted its outlook on P3 Health, lowering the price target from $12.50 to $8.00, while maintaining a Hold rating.

P3 Health Partners also entered a significant financing agreement with VBC Growth SPV 5, LLC, involving a promissory note and warrants to purchase shares of P3’s Class A common stock. The agreement allows P3 Health Group, LLC to access up to $70 million, with an initial $15 million available immediately. The interest rate on the promissory note is set at 19.5% per annum, and stockholder approval is required for the exercise of warrants. The company’s recent financing aims to support its working capital needs, as disclosed in a recent SEC filing.

The company’s membership declined by 8%, but per member funding increased by 8%, reflecting improved efficiency. Despite the revenue shortfall, P3 Health Partners managed to achieve a $20 million improvement in operating efficiency. The company reaffirmed its full-year 2025 guidance, anticipating significant improvements in the latter half of the year. In light of these developments, P3 Health Partners continues to focus on enhancing its value-based care partnerships and operational efficiencies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.